These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 20547991)

  • 1. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
    Konstantinopoulos PA; Spentzos D; Karlan BY; Taniguchi T; Fountzilas E; Francoeur N; Levine DA; Cannistra SA
    J Clin Oncol; 2010 Aug; 28(22):3555-61. PubMed ID: 20547991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
    Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
    Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
    Gadducci A; Guerrieri ME
    Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
    Hennessy BT; Timms KM; Carey MS; Gutin A; Meyer LA; Flake DD; Abkevich V; Potter J; Pruss D; Glenn P; Li Y; Li J; Gonzalez-Angulo AM; McCune KS; Markman M; Broaddus RR; Lanchbury JS; Lu KH; Mills GB
    J Clin Oncol; 2010 Aug; 28(22):3570-6. PubMed ID: 20606085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
    PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
    Zhang M; Liu G; Xue F; Edwards R; Sood AK; Zhang W; Yang D
    Gynecol Oncol; 2016 Apr; 141(1):57-64. PubMed ID: 27016230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on PARP1 inhibitors in ovarian cancer.
    Sessa C
    Ann Oncol; 2011 Dec; 22 Suppl 8():viii72-viii76. PubMed ID: 22180407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
    Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
    Steffensen KD; Adimi P; Jakobsen A
    Int J Gynecol Cancer; 2017 Nov; 27(9):1842-1849. PubMed ID: 28763368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
    Gadducci A; Guerrieri ME
    Crit Rev Oncol Hematol; 2017 Jun; 114():153-165. PubMed ID: 28477743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer treatment in mutation carriers/BRCAness.
    Lorusso D; Perotto S
    Minerva Ginecol; 2016 Oct; 68(5):566-78. PubMed ID: 26785283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations.
    Ragupathy K; Ferguson M
    J Obstet Gynaecol; 2011; 31(2):178-9. PubMed ID: 21281038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.